10-K: United-Guardian Reports Increased Sales and Profitability in 2024 Annual Results

United-Guardian, Inc. reports a 12% increase in sales and improved profitability for the fiscal year ended December 31, 2024, driven by strong performance in cosmetic ingredients.

Summary

• United-Guardian, Inc. reported a 12% increase in sales, reaching $12.18 million in 2024 compared to $10.88 million in 2023.
• The increase in sales was primarily driven by a 51% increase in cosmetic ingredient sales to Ashland Specialty Ingredients (ASI), the company's largest distributor.
• Gross profit margin improved to 53% in 2024 from 50% in 2023, attributed to higher sales of cosmetic ingredients and lower per-unit overhead costs.
• Operating expenses increased by 13% to $2.36 million, due to increased sales and marketing expenses, payroll, and board of directors' fees.
• Net income increased to $3.25 million in 2024, compared to $2.58 million in 2023.
• Earnings per share (basic and diluted) increased to $0.71 in 2024 from $0.56 in 2023.
• The company declared cash dividends of $0.60 per share in 2024, compared to $0.10 per share in 2023.
• The company anticipates beginning manufacturing and reporting sales of its new Natrajel line of sexual wellness ingredients in 2025.
• The company's ISO 9001:2015 certification is valid through July 22, 2027.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with increased sales, improved profitability, and strategic initiatives for future growth. While there are some risks and challenges, the overall tone is optimistic and suggests a healthy financial performance.

Positives

• Increased sales and profitability driven by strong performance in cosmetic ingredients.
• Improved gross profit margin due to higher sales of higher-margin products and lower overhead costs.
• Strong cash flow from operations, generating $3.47 million in 2024 compared to $3.14 million in 2023.
• The company is well-positioned for future growth with a refined product portfolio and strategic partnerships.
• The company anticipates beginning manufacturing and reporting sales of its new Natrajel line of sexual wellness ingredients in 2025.
• The company's ISO 9001:2015 certification is valid through July 22, 2027.

Negatives

• Operating expenses increased by 13% due to increased sales and marketing expenses, payroll, and board of directors' fees.
• Pharmaceutical sales decreased by approximately 5% in 2024 compared with the same period in 2023.
• The company is still in the process of renegotiating some of its marketing and distribution agreements.
• The company discontinued its industrial product line after the second quarter of 2023 due to low sales volume with no growth prospects.

Risks

• Continued global supply chain instability and potential tariffs could impact raw material costs and availability.
• The company faces competition from lower-cost competitors, particularly in the cosmetic ingredients market.
• The company relies on a small number of distributors and customers, creating concentration risk.
• The company depends on one contract manufacturer for the production of its pharmaceutical product, Renacidin.
• The company is subject to government regulations, including FDA and environmental regulations, which could impact its operations and costs.
• The company is exposed to cybersecurity risks, which could disrupt its operations and compromise sensitive information.

Future Outlook

The company anticipates beginning manufacturing and reporting sales of its new Natrajel line of sexual wellness ingredients in 2025 and expects research and development expenses to increase modestly during 2025.

Industry Context

The company primarily competes in the specialty ingredients space, which is characterized by a broad range of product lines and competition based on product performance, price, quality, service, and innovation. The company is strengthening its core capabilities and investing in product development, especially in naturally derived products, to improve its competitive position.

Comparison to Industry Standards

• It is difficult to make a direct comparison to industry standards without knowing the specific sub-segments within specialty ingredients that United-Guardian competes.
• Ashland Specialty Ingredients (ASI), a key distributor, is a business segment of Ashland, Inc., a larger company with an extensive line of personal care and pharmaceutical additives.
• Croda International Plc., the parent company of Sederma SAS, is a major player in specialty chemicals and ingredients, providing a broader range of products and services than United-Guardian.
• Brenntag Specialties, the distributor for the Natrajel line, is a global market leader in chemicals and ingredients distribution, offering a wide range of products and services to various industries.

Related Party Transactions

• The company made payments of $20,000 and $100,000 respectively, to Ken Globus, the company's former President, for consulting services subsequent to his departure from the company.
• The company paid PKF OConnor Davies $23,250 and $20,000, respectively, for accounting and tax services.

Stakeholder Impact

• Shareholders: Increased profitability and dividends are positive for shareholders.
• Employees: The company is committed to paying employees in a fair and equitable manner and offers a competitive benefits program.
• Customers: The company is focused on providing high-quality products and technical expertise to meet customer needs.
• Suppliers: The company maintains relationships with multiple suppliers and is committed to sustainable procurement practices.

Next Steps

• Finalize a new distribution agreement with ASI by the end of the second quarter of 2025.
• Begin manufacturing and reporting sales of the new Natrajel line of sexual wellness ingredients in 2025.
• Continue to monitor and address potential impacts from global supply chain instability and tariffs.
• Continue to invest in product development, especially in naturally derived products.
• Continue to work closely with the network of distributors to price products competitively and expand the customer base.

Key Dates

Keywords

cosmetic ingredients, pharmaceuticals, medical lubricants, sexual wellness, sales, profitability, United-Guardian, financial results, annual report, dividends